?Exir research project of desferoxamin with brand name of Deferoxir

Comparison the efficacy of Deferoxir versus other desferoxamine products in thalassemia major patient

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015012620818N1

Enrollment

100

Registered

2015-02-26

Start date

2014-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thalassemia major. Cooley anaemia Severe beta thalassaemia Thalassaemia: intermedia major

Interventions

Deferoxir vial 500 mg,40 mg/kg,for 6 months.

Treatment - Drugs

Deferoxir vial 500 mg,40 mg/kg,for 6 months

Eligibility

Sex/Gender

All

Age

5 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with major thalassemia under regular blood injection therapy;. age over 5; undergoing treatment with one of deferoxamine pharmaceutical products; Norma renal function; serum cratinine undr 0. 7; in children under the age of 12 less than 1.0; in teenagers less than 1.1; and in over 16 years old pateinets (female less than 1.2; male less than 1.2); Trans aminase enzymes level less than 2 times of normal range; BUN<22mg/dl. Exclusion Criteria: Any experience of allergic reaction to desferoxamine, positive HCV Ab / HBS Ag.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ferritin. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;SGOT. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;SGPT. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;Cr. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;WBC. Timepoint: every 2 weeks. Method of measurement: blood test.;Hgb. Timepoint: every 2 weeks from begining of study. Method of measurement: blood test.;Platlet. Timepoint: every 2 weeks from begining of study. Method of measurement: blood test.	—

Measure

Time frame

Ferritin. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;SGOT. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;SGPT. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;Cr. Timepoint: every 2 month from begining of study. Method of measurement: blood test.;WBC. Timepoint: every 2 weeks. Method of measurement: blood test.;Hgb. Timepoint: every 2 weeks from begining of study. Method of measurement: blood test.;Platlet. Timepoint: every 2 weeks from begining of study. Method of measurement: blood test.

—

Secondary

Measure	Time frame
Optometry. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: optometry.;T2*MRI. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: blood test.;Audiology. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: Audiology.;Sonography. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: Sonography.	—

Measure

Time frame

Optometry. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: optometry.;T2*MRI. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: blood test.;Audiology. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: Audiology.;Sonography. Timepoint: before study,6 months after begining of study,12 months after beginig of study. Method of measurement: Sonography.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mir Azizi

Exir pharmacutical company

shahla.mirazizi@gmail.com+98 21 8891 8475

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026